Rigosertib sodium is a non-ATP-competitive inhibitor of PLK1 (IC50 value of 9–10 nM) which induces mitotic arrest of tumor cells characterized by spindle abnormalities leading to their apoptosis. In vitro studies with Rigosertib sodium showed that incubation of human leukemic cells with this compound results in the inhibition of PI3K/AKT pathway, down regulation of cyclin D1, induction of NOXA and BIM and activation of JNK pathway. In vivo, Rigosertib sodium did not exhibit hematotoxicity, liver damage, or neurotoxicity, and was a potent inhibitor of tumor growth in a variety of xenograft nude mouse models.

KEYWORDS: Rigosertib sodium | supplier | PLK1 inhibitor | ON01910 sodium | Estybon | ON-01910 sodium | ON 01910 sodium | CAS [592542-60-4] | [592542-59-1] | Non Selective (CHK2; p53) | PLK | Inhibitor | Enzymes | Novonex | ON 01910.Na